Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors

Summary Background . Ataxia telangiectasia mutated (ATM) kinase orchestrates DNA double strand break (DSB) repair; ATM inhibitors may therefore enhance the therapeutic effect of DSB-inducing treatments such as radiotherapy (RT). M3541 is an orally administered selective inhibitor of ATM. Methods. Th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2022-06, Vol.40 (3), p.596-605
Hauptverfasser:	Waqar, Saiama N., Robinson, Clifford, Olszanski, Anthony J., Spira, Alexander, Hackmaster, Melissa, Lucas, Luisa, Sponton, Laura, Jin, Hulin, Hering, Ursula, Cronier, Damien, Grinberg, Marianna, Seithel-Keuth, Annick, Diaz-Padilla, Ivan, Berlin, Jordan
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibiotics Anticancer properties Antitumor activity Ataxia Ataxia telangiectasia Ataxia Telangiectasia - chemically induced Ataxia Telangiectasia - drug therapy Ataxia telangiectasia mutated protein Ataxia Telangiectasia Mutated Proteins Bayes Theorem Bayesian analysis Confidence intervals DNA damage Dosage Dose-Response Relationship, Drug Double-strand break repair Humans Immune system Kinases Maximum Tolerated Dose Medicine Medicine & Public Health Neoplasms - drug therapy Neoplasms - radiotherapy Neutropenia Oncology Oral administration Overdose Palliation Patients Pharmacokinetics Pharmacology/Toxicology Phase I Studies Plasma levels Protein Kinase Inhibitors - adverse effects Radiation therapy Regression models Solid tumors Statistical analysis Toxicity Tumors Urinary tract
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!